Kimball Electronics Inc (KE) (Q1 2027) Earnings Call Highlights: Medical Momentum Drives

Kimball Electronics (KE) reported Q1 2027 net sales of $391M, up 7% YoY, with medical sales growing 14%. Adjusted net income fell to $6.1M from $12.3M YoY. Full-year sales guidance is expected at the high end of the range, driven by medical strength and the HealthWet acquisition. Inventory increased by $40M, and the tax rate spiked to 66.1% due to acquisition-related withholding taxes.

Original reporting
Published Nov 6, 2026, 1:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 1:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kimball Electronics Inc (KE) (Q1 2027) Earnings Call Highlights: Medical Momentum Drives — source image
Decision brief

The 30-second read

$KENeutralMed
01

Why it matters

The earnings release provides fresh guidance and highlights operational challenges, offering traders a basis for short‑term positioning.

02

Market read

Kimball's earnings and guidance affect its stock and may influence related medical electronics and CDMO peers.

03

What to watch

The upcoming Indianapolis facility ramp and potential rebrand to Kimball Solutions could unlock new market opportunities.

Relevance 8/10Novelty 8/10Timing: after-hours following Q1 earnings call

Background

Kimball Electronics reported Q1 results with mixed performance: revenue up, but margins and tax rate deteriorated. Management highlighted medical segment strength and integration of recent acquisitions.

Company-level read

Ticker impact

$KENeutralHigh confidence
Context

Q1 2026 earnings released with net sales $391M, EPS $0.25, and FY2027 sales guidance $1.535‑$1.560B.

Expected impact

likely modest downside as investors price in lower margins and high tax rate, offset by strong medical growth guidance.

Evidence & confidence

The earnings numbers are new and materially affect valuation; margin compression and tax hit are immediate concerns, while medical guidance supports upside.

Market effects

Medical electronics demand may lift peers in the CDMO space, while automotive and climate control segments face headwinds.

U.S. and North American suppliers could see inventory pressure from component tightness.

Kimball's medical growth signals broader strength in the global medical device manufacturing market.

Counterpoint

Investors could view the strong medical sales and high‑end guidance as a catalyst for upside despite margin pressure.

Key entities

  • Kimball Electronics Inc

    U.S. electronics manufacturer (ticker KE).

  • Janet Croom

    Chief Financial Officer of Kimball Electronics.

  • Rick Phillips

    Chief Executive Officer of Kimball Electronics.

Related articles

HighAI 8/10

Kimball Electronics (KE) Q1 2027 Earnings Call Transcript

Kimball Electronics (KE) reported Q1 2027 net sales of $391M, up 7% YoY, driven by growth in medical, industrial, and automotive sectors. Medical sales increased 14% YoY to $116M, while automotive sales rose 4% to $171M. The company reiterated full-year sales guidance of $1.535B-$1.560B, with adjusted operating income expected between 4.4% and 4.7% of net sales. KE is investing in growth initiatives, including the integration of Helvoet, and expects top-line synergies.

$KELow

KIMBALL ELECTRONICS REPORTS Q1 RESULTS HIGHLIGHTED BY THE RETURN TO TOP-LINE GROWTH; COMPANY REITERATES GUIDANCE FOR FISCAL 2027 WITH SALES EXPECTED AT THE…

Kimball Electronics, Inc. (KE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 KIMBALL ELECTRONICS REPORTS Q1 RESULTS HIGHLIGHTED BY THE RETURN TO TOP-LINE GROWTH; COMPANY REITERATES GUIDANCE FOR FISCAL 2027 WITH SALES EXPECTED AT THE HIGH END OF THE RANGE JASPER, Ind., November 4, 2026 -- (BUSINESS WIRE) -- Kimball Electronics, Inc. (Nasdaq: K